X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
STRIDES PHARMA SCIENCE Quarterly Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE Quarterly Results    (PLLB)

Here are the latest quarterly results of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE financial fact sheet and STRIDES PHARMA SCIENCE share price and chart. For a sector overview, read our pharmaceuticals sector report.

Excel Export | Annual Financial Info | Result Scoreboard

STRIDES PHARMA SCIENCE Quarterly Results

No. of Mths
Qtr. Ending
3
Jun-17
*
3
Sep-17
*
3
Dec-17
*
3
Mar-18
*
3
Jun-18
*
3
Sep-18
*
3
Dec-18
*
3
Mar-19
*
8-Qtr Chart
Click to enlarge
Net Sales Rs m8,4189,9567,4906,6426,6357,3267,9458,397 
Other income Rs m361223157218106778146 
Turnover Rs m8,77810,1797,6476,8606,7417,4047,9538,543 
Expenses Rs m7,5458,6446,2625,7765,8276,3306,6746,808 
Gross profit Rs m8461,1731,1666497589221,2781,679 
Depreciation Rs m511543391443429445407438 
Interest Rs m640619498455441485501627 
Profit before tax Rs m55234434-31-570379760 
Tax Rs m-3342-2-40-431663111 
Profit after tax Rs m8819343583854316650 
Gross profit margin %10.111.815.69.811.412.616.120.0 
Effective tax rate %-60.717.8-0.4125.8837.323.116.714.5 
Net profit margin %1.11.95.80.10.60.74.07.7 
Diluted EPS Rs 1.5 3.2 7.3 0.1 0.6 0.9 5.3 10.9  
Diluted EPS (TTM) Rs 61.9 52.7 28.6 12.1 11.3 9.0 7.0 17.7  
 Subscriber Feature                  
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Read: STRIDES PHARMA SCIENCE 4QFY19 Result Performance Review

More Pharmaceuticals Company Quarterly Results:   NOVARTIS  IPCA LABS  DR. REDDYS LAB  PLETHICO PHARMA  INDRAPRASTHA MEDICAL  

Compare STRIDES PHARMA SCIENCE With:   NOVARTIS  IPCA LABS  DR. REDDYS LAB  PLETHICO PHARMA  INDRAPRASTHA MEDICAL  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End on a Positive Note for Third Straight Day; Yes Bank Falls 5%(Closing)

Indian share markets traded on a positive note most of the day and ended marginally higher. Sectoral indices ended on a mixed note with stocks in the IT sector.

Views on news

STRIDES PHARMA SCIENCE Plunges by 6%; BSE HEALTHCARE Index Down 0.4% (Market Updates)

Jul 17, 2019 | Updated on Jul 17, 2019

STRIDES PHARMA SCIENCE share price has plunged by 6% and its current market price is Rs 370. The BSE HEALTHCARE is down by 0.4%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 3.5%) and PFIZER (up 2.5%). The top losers is STRIDES PHARMA SCIENCE (down 5.6%)..

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

A One Stock Crorepati (Profit Hunter)

Jul 4, 2019

Do you wish you could become a crorepati in the stock market? Read on...

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors (The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Union Budget 2019-2020: More Style Over Substance (The 5 Minute Wrapup)

Jul 5, 2019

Did the Union Budget announce measures to stimulate the economy and bolster corporate earnings growth?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Jul 17, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - TEVA PHARMA COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS